MISSION
Menzies exists to perform internationally significant medical research leading to healthier, longer and better lives for Tasmanians.
Menzies exists to perform internationally significant medical research leading to healthier, longer and better lives for Tasmanians.
We work to improve prevention and management of important health problems that impact large sections of our population. We focus on lifestyle and environmental risk factors, obesity, multiple sclerosis and mental health.
Brain diseases like multiple sclerosis and motor neurone disease affect many Australians and impact movement and memory. Our research focus is to discover the causes of each disease and develop effective treatments to guard the nervous system.
We focus on the prevention and management of cardiovascular and respiratory diseases. Our aim is to reduce the impact of stroke, heart and lung disease.
Our research focuses on common bone and joint diseases, including osteoarthritis.
Our priorities are to understand the genetic and molecular cause of cancer, blinding eye diseases and multiple sclerosis, and share this knowledge to prevent, diagnose and treat diseases.
Professor Martin Hensher’s modelling on Long Covid showed that a minimum of 160,000 Australians will be experiencing Long Covid by the end of 2022. The report also found that over 500,000 people will have Long Covid symptoms and that more than 110,000 of them will suffer significant impacts. He called on the Australian Government to listen to health professionals and act on the recommendations.
We began the phase two trial TAURUS.2 which is assessing the effects of magnetic brain stimulation (MBS) on multiple sclerosis and is being rolled out to six sites nationally. It will also use advanced brain imaging techniques such as MRI to assess whether MBS effectively increases myelin levels in the brain.
The results of a global study that began at Menzies were published in the New England Journal of Medicine and confirmed that risk factors present in childhood are directly related to heart attacks, stroke and other cardiovascular problems later in life. More than 40,000 participants worldwide were tracked for several decades.
Professor Peter Dargaville and his collaborator Dr Tim Gale currently have a licence in place for the “OxyGenie tm” technology with UK based SLE Ltd. Discussions are underway to vary the existing licence agreement by adding the USA and Canada and also revising royalty rates.
Professor Fay Johnston and Dr Penelope Jones continue to work with the University of Melbourne to combine the “AirRater” app with the “Melbourne Pollen” app with a view to creating a new company.
Breakthroughs in our research into a bait delivered vaccine for the Devil Facial Tumour Disease and the publication of four new papers has led to momentum which could stop Devil Facial Tumour Disease 2 before it spreads across Tasmania and perhaps even eliminate Devil Facial Tumour Disease 1.
On average, each week we had a casual staff working the equivalent of 5.36 FTE through 2022.
Students
Masters students: 3
PhD students: 85
Honour students: 12
For outstanding research achievement evidenced through publication in a scholarly journal.
Professor Mark Nelson
‘Safety of ceasing aspirin used without a clinical indication after age 70 years: a subgroup analysis of ASPREE randomized trial’, published in Annals of Internal Medicine.
To recognise research that has had demonstrable benefits to society.
Professor Ingrid van der Mei
For translation and end user uptake of research that has had a demonstrable benefit to society.
▼ Menzies excellence awards
Hoang Phan
‘Factors contributing to sex differences in health-related quality of life (HRQoL) after ischemic stroke: the Brain Attack Surveillance In Corpus Christi (BASIC) project’, published in The Journal of American Heart Association.
Amin Zarghami
‘Long-term trajectories of employment status, workhours, and disability support pension status, after a first episode of CNS demyelination’, published in The Multiple Sclerosis Journal.
Verity Cleland and Jing Tian
‘Body-mass index trajectories from childhood to mid-adulthood and their sociodemographic predictors: Evidence from the International Childhood Cardiovascular Cohort (i3C) Consortium’, published in EClinicalMedicine.
Chrissie Ong
‘Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours’, published in Open Biology
Johanna Jones
‘Pathogenic genetic variants identified in Australian families with paediatric cataract’, published in BMJ Open Ophthalmology.
Xin Lin
‘Novel plasma and brain proteins that are implicated in multiple sclerosis’, published in Brain: A Journal of Neurology.
Laura Laslett
‘Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life’, published in The Journal of Neurology Neurosurgery and Psychiatry.
Dean Picone
‘Validation Status of Blood Pressure Measuring Devices Sold Globally’, published in The Journal of the American Medical Association.
Sionne Lucas
‘Preclinical interstitial lung disease in relatives of familial pulmonary fibrosis patients’, published in Pulmonology.
Professor Kathryn Burdon
For recognition of significant and ongoing contributions made to the career and professional development of staff and students
Natasha Stevens
For outstanding and exceptional leadership of the MS Research Flagship and contribution to its further development.
Mark Bennett
For an outstanding contribution to the leadership of Menzies and an exceptional commitment to the delivery of its mission to perform significant medical research leading to better lives for Tasmanians.
Dr Suzi Claflin from our MS Research Flagship was the recipient of the prestigious Young Tall Poppy Science Award 2022 for her work in helping the community better understand multiple sclerosis.
MS Australia (MSA) held a 50th year anniversary dinner and recognised Menzies as a medal recipient in recognition of our “unwavering and passionate dedication, recognising the outstanding, consistent and selfless service and many contributions towards the MS movement in Australia”. Professor Bruce Taylor and Dr Suzi Claflin were awarded individual medals.
In November Australia’s biggest investment conference, Sohn Hearts & Minds, was held in Hobart. We were fortunate to be the beneficiary of their philanthropic efforts and our lead environmental health researcher, Professor Fay Johnston, gave the keynote presentation about her work dedicated to improving the quality of air that we breathe.
Professor Peter Dargaville was a finalist in the Tasmanian Australian of the Year Awards. He was nominated for his outstanding work helping pre-term babies around the world breathe.
Professor Bruce Taylor was awarded a prestigious fellowship with the Australian Academy of Health and Medical Sciences.
Professor Mark Nelson was awarded the Peter Mudge Medal by the Royal Australian College of General Practitioners (RACGP). This award is made annually to a RACGP Fellow who has advanced the discipline of general practice and the goals of the college, and whose original research has the most potential to significantly influence daily general practice.
▲ Professor Fay JohnstonThe Menzies MS Research Flagship is working hard to reduce the impact of multiple sclerosis (MS) for individuals and the community, in Tasmania and beyond.
In 2022 we;
• Launched a national, ground-breaking, phase II clinical trial aiming to stop and reverse the symptoms of MS through brain repair mechanisms.
• Achieved world wide recognition for Understanding MS, one of the top ten online courses in the world, which has improved knowledge and understanding of MS, health literacy and self-efficacy, with >36,000 participants from >130 countries.
• Celebrated 20 years of the Australian MS longitudinal study (AMSLS) and launched the MS nurses report, advocating for increased federal funding and equity of access to care in Australia.
• Created an MS stem cell biobank to further national and international research efforts to understand the biological causes of MS and advance the discovery of new treatments.
Number of Grants
The number of peer reviewed research publications. This is the interim number or refereed articles in scholarly journals from Menzies in 2022. The final number for 2021 was 382.
Major Grants – 13
Minor Grants – 14
Honorary fellowship – 1
Grant Value
$7,359,295
Major Grants – $6,832,513
Minor Grants – $526,782
Thank you to all who support our work with a gift; we are incredibly grateful for your generosity as we celebrate the genuine difference that philanthropy is making to research at Menzies.
During 2022, we strengthened our commitment to building the capacity of future medical researchers with 23 of our students and staff supported by either a philanthropically funded scholarship or a fellowship – all of which are enabled by the generosity of our local community.
If we are to improve the health of Tasmanians, our continued work here at the Menzies is vital. Your donations fund research projects, provide student scholarships, support our researchers and fund the purchase of significant research equipment. And importantly, your generosity often provides critical early funding to many of our research projects which then go on to attract substantial nationally competitive funding.
Thank you for your unwavering support that helps to advance our research for the benefit of all. Your gift –large or small – makes a difference whether you donate to our appeal, make a planned gift in your will, or give a donation in memory of a loved one. Thank you for joining us here at Menzies to create better health opportunities and lives for Tasmanians. menzies.utas.edu.au/get-involved
All donations over $2 are tax deductible (in Australia). Donations can be made to Menzies Institute for Medical Research, at the University of Tasmania.
1,619 Donors
$590,916 Bequests
23 Philanthropically funded scholarships and fellowships
2,675 Individual gifts
$2.2M Donations
132 Recurring donors
National and International Print, Television, Radio and Online Media 440
Media mentions
As at 31 December 2022, the University of Tasmania held investment funds valued at $30,029,188 for the purpose of supporting research at Menzies. Investment returns provide a source of research income for Menzies and these funds are disbursed in accordance with donors’ wishes.
The investment portfolio is managed by the Investment Advisory Panel, comprising of University staff and industry professionals, which provide oversight and stewardship of the investment portfolio and advice on investment strategy and policy.
In 2022 we farewelled our Director, Distinguished Professor Alison Venn. Starting in the role in 2016 Alison led Menzies through a period of growth and consolidation. In that time, we saw record yearly publications and funding, the establishment of the Multiple Sclerosis Research Flagship and subsequent $10 million in federal government funding, as well as our first commercially licenced research invention, the OxyGenie™, which helps premature babies to breathe. We now have a stronger focus on working in cross-disciplinary teams and developing partnerships outside academia, including with health consumers and health services, which helps ensure our research meets community needs. Alison continues her research in an honorary capacity.
We also farewelled Professor Leigh Blizzard and Tim Albion, Senior Database Administrator, both who had been with Menzies for over two decades. Alison and Leigh have been appointed as Emeritus Professors to acknowledge their contributions and tenure. Leigh was also named the Inaugural Fellow of the Australasian Epidemiological Association.
Professor Moira Clay (Chair)
Distinguished Professor Alison Venn (Director)
Professor Denise Fassett
Professor Anthony Koutoulis
Ms Philippa Leedham
Professor Stephen Tong
Professor Geoffrey Donnan
Ms Rebecca Kardos
Mr Edward Kemp